Achieving patient buy-in and long term compliance with antihypertensive treatment

被引:3
|
作者
Garfield, FB [1 ]
Caro, JJ [1 ]
机构
[1] Caro Res, Concord, MA 01742 USA
关键词
D O I
10.2165/00115677-200007010-00003
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Noncompliance is a major problem in antihypertensive treatment, Up to 50% of patients are noncompliant after 1 year and 85% after 5 years. Current approaches for predicting compliance are based on patient demographics, medication characteristics and clinical factors, health beliefs and the quality of patient-provider communication. All of these factors together predict compliance only less than half the time, indicating that over half of the patients in disease management programmes may not buy-in to their treatment. A new approach views compliance as behaviour change that takes place over time. Patients move through 5 stages in their 'readiness to comply'. Our study of over 700 patients with hypertension using brief self-report measures to assess their 'readiness to comply' found a highly significant relationship between 'readiness to comply' and reported compliance. Clinicians can increase patient buy-in and long term compliance by assessing their patients 'stage-of-change' using validated measures and then matching their interventions to each patient's 'readiness to comply'. Physicians who treat patients with hypertension know that compliance with outpatient drug therapy is a major problem in disease management. Over the last 35 years, many clinicians and clinical researchers have tried to solve this problem but their attempts to Set patients to consistently take their medication have been, at most, partially successful. Even those able to somewhat increase compliance have turned out to be very costly in terms of both resources and pcrsonnel.([1]) This paper describes what has and has not worked to improve patient compliance, and includes new ideas about compliance from research in behavioural medicine. In addition, it makes some suggestions, based on research, of what can be done to increase patients' involvement with, and adherence to, treatment. These interventions do not have to be costly in terms of time, personnel or resources but, for them to be effective, they have to be customised to the individual needs of each patient. To do so, a patient's 'readiness to comply' has to be assessed carefully.
引用
收藏
页码:13 / 20
页数:8
相关论文
共 50 条
  • [41] VARIATIONS IN PATIENT COMPLIANCE WITH COMMON LONG-TERM DRUGS
    INUI, TS
    CARTER, WB
    PECORARO, RE
    PEARLMAN, RA
    DOHAN, JJ
    CLINICAL RESEARCH, 1980, 28 (02): : A295 - A295
  • [42] Designing AI-augmented healthcare delivery systems for physician buy-in and patient acceptance
    Dai, Tinglong
    Tayur, Sridhar
    PRODUCTION AND OPERATIONS MANAGEMENT, 2022, 31 (12) : 4443 - 4451
  • [43] Compliance with long-term treatment in patients with osteoporosis
    Adachi, D.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S111 - S112
  • [44] CARDIOVASCULAR AND RENAL EFFECTS OF LONG-TERM ANTIHYPERTENSIVE TREATMENT
    HARTFORD, M
    WENDELHAG, I
    BERGLUND, G
    WALLENTIN, I
    LJUNGMAN, S
    WIKSTRAND, J
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 259 (17): : 2553 - 2557
  • [45] ANTIHYPERTENSIVE AND METABOLIC EFFECTS OF A LONG-TERM TREATMENT WITH ACEBUTOLOL
    GIUNTOLI, F
    SCALABRINO, A
    GALEONE, F
    BIRINDELLI, A
    NATALI, A
    PANIGADA, G
    SABA, P
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1984, 36 (01): : 188 - 194
  • [46] LONG-TERM HEMODYNAMIC-EFFECTS OF ANTIHYPERTENSIVE TREATMENT
    LUNDJOHANSEN, P
    OMVIK, P
    NORDREHAUG, JE
    CLINICAL INVESTIGATOR, 1992, 70 (02): : S58 - S64
  • [47] LONG-TERM COAGULATION STUDIES IN PATIENTS ON ANTIHYPERTENSIVE TREATMENT
    SCHRADER, J
    SALZER, UM
    GERHARDY, M
    KOSTERING, H
    SCHELER, F
    THROMBOSIS AND HAEMOSTASIS, 1983, 50 (01) : 135 - 135
  • [48] ANTIHYPERTENSIVE AND METABOLIC EFFECTS OF LONG-TERM TREATMENT WITH INDENOLOL
    SABA, P
    GIUNTOLI, P
    GALEONE, F
    GABBIANI, S
    NATALI, A
    GROOTHOLD, G
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1989, 45 (05): : 775 - 781
  • [49] Does antihypertensive treatment have long-term benefits?
    Giuseppe Mancia
    Nature Reviews Cardiology, 2012, 9 : 130 - 132
  • [50] ANTIHYPERTENSIVE AND METABOLIC EFFECTS OF LONG-TERM TREATMENT WITH INDORAMIN
    GIUNTOLI, F
    GALEONE, F
    NANNINI, E
    NATALI, A
    GABBANI, S
    PANIGADA, G
    SABA, P
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1987, 42 (02): : 219 - 224